Sun Pharma Advanced Research Company Limited (SPARC.BO)

219,50 +0,90 (+0,41%) Börsenschluss: 12:30PM IST

Sun Pharma Advanced Research Company Limited

17/B, Mahal Industrial Estate
Off Mahakali Caves Road Andheri (East)
Mumbai 400093
India
91 22 6645 5645
https://www.sparc.life

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 407

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Anilkumar Raghavan	Chief Executive Officer	N/A	N/A	1968
Mr. Chetan M. Rajpara	Chief Financial Officer	15,14M	N/A	N/A
Mr. Jaydeep Issrani	Senior General Manager of Business Development, Corporate Communication & Investor Relations	N/A	N/A	N/A
Ms. Shanta Gupta	Chief Human Resource Officer	N/A	N/A	N/A
Dr. Nitin Dharmadhikari	Head COE's	N/A	N/A	1962
Mr. Siu-Long Yao	Head Clinical Development	N/A	N/A	N/A
Dr. Nitin K. Damle Ph.D.	Chief Innovation Officer	N/A	N/A	N/A
Mr. Yashoraj Zala	Head of Drug Delivery Systems	N/A	N/A	N/A
Mr. Vikram Ramanathan	Head of Preclinical Development	N/A	N/A	N/A
Dr. Venkata Palle	Global Head of Drug Discovery & Preclinical Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in INR.

Beschreibung

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India.

Corporate Governance

Sun Pharma Advanced Research Company Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.